Literature DB >> 20952463

Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus.

Taraneh Mehrani1, Michelle Petri.   

Abstract

OBJECTIVE: IgA isotypes of anticardiolipin and anti-ß(2) glycoprotein I (anti-ß(2)-GPI) are omitted from the revised antiphospholipid syndrome (APS) classification criteria. Multiple studies have found a high prevalence of IgA anti-ß(2)-GPI in systemic lupus erythematosus (SLE). We determined the frequency and associations of IgA anti-ß(2)-GPI in a cohort of patients with SLE.
METHODS: anti-ß(2)-GPI was measured in 796 patients with SLE (93% women, 53% white, 38% African American, mean age 45 yrs). IgA anti-ß(2)-GPI (> 20 phospholipid units) was found in 20%. Using a cohort database, associations with cumulative thrombotic and other manifestations were determined.
RESULTS: of patients with SLE who demonstrated IgA anti-ß(2)-GPI positivity, about 6% had transient ischemic attack (p = 0.070), 4% had superficial thrombophlebitis (p = 0.647), 20% had deep venous thrombosis (p = 0.003), 4% had other venous thrombosis (p = 0.827), 12% had stroke (p = 0.050), and 1% had myocardial infarction (p = 0.397).
CONCLUSION: IgG anti-ß(2)-GPI has the strongest association with thrombosis in SLE. However, IgA anti-ß(2)-GPI was more strongly associated with deep venous thrombosis and with stroke than was IgM. These results indicate that assessment of IgA anti-ß(2)-GPI is associated with thrombosis in SLE, and that the classification criteria for APS should be revised to include IgA anti-ß(2)-GPI in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952463     DOI: 10.3899/jrheum.100568

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Authors:  Ozan Unlu; Doruk Erkan; Medha Barbhaiya; Danieli Andrade; Iana Nascimento; Renata Rosa; Alessandra Banzato; Vittorio Pengo; Amaia Ugarte; Maria Gerosa; Lanlan Ji; Maria Efthymiou; D Ware Branch; Guilherme Ramires de Jesus; Angela Tincani; H Michael Belmont; Paul R Fortin; Michelle Petri; Esther Rodriguez; Guillermo J Pons-Estel; Jason S Knight; Tatsuya Atsumi; Rohan Willis; Stephane Zuily; Maria G Tektonidou
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-01       Impact factor: 4.794

Review 3.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

4.  Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome.

Authors:  Michelle Petri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Authors:  Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2012-08

6.  Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus.

Authors:  Ehtisham Akhter; Zakera Shums; Gary L Norman; Walter Binder; Hong Fang; Michelle Petri
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

7.  Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Authors:  Vijaya Murthy; Rohan Willis; Zurina Romay-Penabad; Patricia Ruiz-Limón; Laura A Martínez-Martínez; Shraddha Jatwani; Praveen Jajoria; Alan Seif; Graciela S Alarcón; Elizabeth Papalardo; Jigna Liu; Luis M Vilá; Gerald McGwin; Terry A McNearney; Rashmi Maganti; Prashanth Sunkureddi; Trisha Parekh; Michael Tarantino; Ehtisham Akhter; Hong Fang; Emilio B Gonzalez; Walter R Binder; Gary L Norman; Zakera Shums; Marius Teodorescu; John D Reveille; Michelle Petri; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2013-12

8.  Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome.

Authors:  Sabiha Anis; Ejaz Ahmed; Rana Muzaffar
Journal:  J Nephropathol       Date:  2013-07-01

9.  Guillain-Barré syndrome as first presentation of systemic lupus erythematosus: a rare manifestation complicated by IVIg-induced splenic infarct.

Authors:  Richard M Fazio; Ioana Chen; Navjot Somal
Journal:  BMJ Case Rep       Date:  2015-11-25

Review 10.  Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies.

Authors:  Laura Andreoli; Micaela Fredi; Cecilia Nalli; Silvia Piantoni; Rossella Reggia; Francesca Dall'Ara; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.